BioCentury
ARTICLE | Clinical News

Alimta pemetrexed: Phase III final data

June 22, 2015 7:00 AM UTC

Alimta is approved in the U.S. and EU in combination with cisplatin for first-line treatment of non-squamous NSCLC, and for maintenance and second-line treatment of non-squamous NSCLC. The drug is als...